Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 4/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.49 |
| ▸ | MLNR | O43193 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PGR | P06401 | 2/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1152231 | 0.99 | POLB (0.53) | POLBHSD17B10OPRM1CHRM1CHRM2 | |
| SCHEMBL1153122 | 0.90 | CHRM1 (0.52) | POLBHSD17B10OPRM1CHRM1DRD2 | |
| SCHEMBL11593801 | 0.90 | OPRM1 (0.55) | OPRM1CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL11595473 | 0.90 | OPRM1 (0.56) | OPRM1CHRM1CHRM2CHRM4CHRM3 | |
| Hydrochloric Acid SCHEMBL11594931 | 0.89 | OPRM1 (0.55) | OPRM1CHRM1CHRM2CHRM4CHRM3 | |
| Hydrochloric Acid SCHEMBL1152327 | 0.89 | CHRM1 (0.51) | POLBHSD17B10OPRM1CHRM1DRD2 | |
| SCHEMBL11593459 | 0.87 | DRD2 (0.51) | OPRM1CHRM1DRD2HTR1AHTR2A | |
| SCHEMBL11593726 | 0.85 | CHRM1 (0.46) | POLBHSD17B10OPRM1CHRM1DRD2 | |
| SCHEMBL1152107 | 0.81 | CHRM1 (0.64) | POLBHSD17B10OPRM1CHRM1CHRM2 | |
| SCHEMBL1153304 | 0.79 | CHRM1 (0.50) | POLBHSD17B10OPRM1CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4076821-A | 4,4-Diphenylcycloalkylpiperidines and psychotropic compositions thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JA) | 1978-02-28 | — | — | US | claimed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | POLB 1168/4885HSD17B10 3104/4885OPRM1 3829/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | POLB 1168/4885HSD17B10 3104/4885OPRM1 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.